Physicians' Academy for Cardiovascular Education

How to address residual risk post ACS: LDL-c, Dyslipdemia, and Inflammation

Meeting report with video, highlights and slides of PACE-CME symposium held at ESC 2016 in Rome

Meeting Impression: How to address residual risk post-ACS: LDL-c, dyslipidemia, and inflammation

News - Oct. 12, 2016
How to address residual risk post-ACS: LDL-c, Dyslipidemia, and inflammation

During a satellite symposium at the ESC 2016 in Rome, organised by PACE-CME, the potential roles of targeting inflammation, LDL-c and dyslipidemia in reducing residual risk were discussed

Novel strategies targeting residual risk: The promise of PCSK9 inhibition

August 30, 2016 - Prof. Erik Stroes (Amsterdam, The Netherlands)
August 30, 2016 - Prof. Erik Stroes (Amsterdam, The Netherlands)

Dr Stroes elaborated on achieving additional LDL-c reduction beyond statins, focussing on PCSK9 inhibitors. He underscored the significance of LDL-c-lowering, as illustrated by the beneficial relation between genetically and therapeutically lower LDL-c and coronary heart disease (CHD) risk and between statin-achieved LDL-c levels and cardiovascular CV risk.

Beyond statins: The role of ezetimibe in targeting residual cardiovascular risk

August 30, 2016 - Chris Packard (Glasgow, UK)
August 30, 2016 - Chris Packard (Glasgow, UK)

ACS patients who are not at LDL-c treatment goal despite statin therapy, currently have two options; increasing statin dose or receiving combination therapy. More cholesterol-lowering drugs are available beyond statins, including ezetimibe, which can be used in combinational setting to further reduce residual CV risk.

Inflammation as potential target for therapy to target residual risk post ACS

News - Aug. 30, 2016
Inflammation as potential target for therapy to target residual risk post ACS

After treatment with high-intensity statins, patients can still have residual cholesterol risk or residual inflammatory risk. This means that patients still have either high levels of LDL-c, but normal high sensitivity C-reactive protein (hsCRP) or normal LDL-c but high hsCRP